Tristan Manalac
Publishes 2 feeds
Biopharma Mergers & Acquisitions
Biopharma Mergers & Acquisitions
11 posts · contributor
FDA News: Approvals, Adcomms, Complete Response Letters and Guidances
FDA News: Approvals, Adcomms, Complete Response Letters and Guidances
11 posts · contributor
Lately
Lawmakers urge FDA to enact new China policies after 3 gene therapy deaths
FDA News: Approvals, Adcomms, Complete Response Letters and Guidances ·
Werewolf and Ambros to tie the knot in $150M rare disease deal
Regeneron wins FDA approval to challenge Ipsen for rare bone disease market
FDA News: Approvals, Adcomms, Complete Response Letters and Guidances ·
Ultragenyx bags first gene therapy approval as previously rejected Sanfilippo asset awaits decision
FDA News: Approvals, Adcomms, Complete Response Letters and Guidances ·
Why pediatric rare oncology outperforms in a volatile biotech market
FDA News: Approvals, Adcomms, Complete Response Letters and Guidances ·
Trump's FDA pick Overton good for psychedelics, new pain meds but bad for vaccines: Analysts
FDA News: Approvals, Adcomms, Complete Response Letters and Guidances ·
Trump picks White House aide Heidi Overton as FDA chief: Reports
FDA News: Approvals, Adcomms, Complete Response Letters and Guidances ·
2026 IPO stock tracker: How newly public biotechs are performing
Amylyx’s redemption story, Summit’s survival woes, Definium’s anxiety win, more
FDA News: Approvals, Adcomms, Complete Response Letters and Guidances ·
Sandoz inks $322M Henlius deal for rights to as many as 10 biosimilars
LEO adds to dermatology portfolio with $435M deal for late-stage rare disease drug
Rebounding biotech funds expected to spur CDMO growth within year
Everything on this page was read from markup Tristan Manalac published — a rel="me" link, an h-card, or the feed’s own author element. Nothing was inferred from anywhere else. To correct or remove it, get in touch. Machine-readable: JSON